Droplet IV

Executive Summary

Droplet IV is a Danish MedTech startup founded in 2020 that has developed an automated, user-friendly device to flush intravenous (IV) lines. The device addresses a critical issue in healthcare: up to 30% of prescribed medication doses are lost due to residual fluid left in IV tubing, leading to suboptimal patient outcomes and significant medical waste. By automating the flushing process, Droplet IV ensures patients receive their full dose, reduces nurse workload by eliminating manual flushing, and decreases biohazard waste. The company operates at the intersection of drug delivery and digital health, offering a simple add-on solution that can integrate with existing IV systems without requiring workflow changes. This innovation holds strong potential to improve medication accuracy, reduce healthcare costs, and enhance sustainability in hospital settings. With its straightforward value proposition and alignment with efficiency-driven healthcare trends, Droplet IV is well-positioned to gain traction in the European MedTech market. However, as a privately held, early-stage company with no disclosed funding, products, or regulatory approvals, execution risk remains significant. The success of Droplet IV hinges on obtaining regulatory approvals, forging partnerships with device distributors or hospital networks, and demonstrating clinical efficacy through pilot studies.

Upcoming Catalysts (preview)

• Q4 2026CE marking or FDA clearance for the IV flushing device40% success
• Q3 2026Clinical pilot study results demonstrating dose accuracy and nurse workflow benefits50% success
• Q2 2026Strategic partnership with a hospital group or IV system manufacturer35% success